Answers are grounded in this paper and cite their sources.
Accumulating evidence suggests that small extracellular vesicles (sEVs) from cord blood–derived stem cells exert therapeutic effects on both degenerative and autoimmune diseases. Cord blood plasma, a ‘by-product’ of mononuclear cell collection, has demonstrated its potential in the treatment of degenerative diseases. Notably, sEVs derived from cord blood plasma (CB-sEVs) play a therapeutic role in regulating tissue regeneration. In this study, we investigated the therapeutic effect of CB-sEVs on type 1 diabetes (T1D). Our data showed that CB-sEVs reduced the incidence of diabetes onset in adoptive-transfer T1D mice, lowered blood glucose levels, and alleviated pancreatic beta-cell inflammation. Furthermore, CB-sEVs significantly inhibited human T cell proliferation following activation with anti-CD3/CD28 beads in vitro. Furthermore, we observed a proportionate decrease of effector T cells and central memory T cells, whereas the percentage of naïve T cells was significantly increased. Additionally, miRNA profiling of CB-sEVs revealed distinct miRNA signatures, providing insights into the active molecular components of CB-sEVs that may drive their therapeutic effects. These findings suggest that CB-sEVs represents a novel promising therapy for T1D.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: